CytoDyn to amend protocol for PRO 140 phase 2 trial in GvHD
CytoDyn announces the IDMC for the PRO 140 Phase 2 trial in graft-versus-host disease has completed a planned interim analysis of trial data on the first 10 patients enrolled. Based on that meeting, the Company plans to amend the trial protocol and obtain concordance for the amended protocol. March 14, 2018